The Latest Breaking News from NM

Hi Hafta team, on the topic of elections, I am curious if there is any intellectual capacity or curiousity for alternate models either in the Indian context or elsewhere with the same five-year term or less governments.  Clearly, it seems to me that short termism in politics is not really…

The Asturias city is home to revered cider, cheese, meat and beans – and a new rail link now makes it easy to get to from Madrid

Navios Maritime Holdings Inc. (NYSE:NM) reported first-quarter revenue growth of 9.3% year-over-year to $127.79 million. Adjusted EPS improved to $0.62 from $(0.50) in 1Q21. Time Charter Equivalent (TCE) for the quarter was $21,767 per day compared to $14,404 per day in 1Q21. Navios Maritime generated cash from operating activities in Q1 of…

Novamind Inc. (OTCQB:NVMDF) (CSE:NM) (FSE:HN2) has been selected by Mind Medicine, Inc. (NASDAQ:MNMD) (NEO:MMED) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults.

Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted share units effective March 11, 2022, to certain executives and employees of the company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from…

Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site.

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication…

Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.

Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.